Document:

EXHIBIT 10.21

     THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS
     WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
     AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK
     ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE,
     PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
     STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE
     SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO AMS
     HEALTH SCIENCES, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

            Right to Purchase up to 495,543 Shares of Common Stock of
                            AMS Health Sciences, Inc.
                   (subject to adjustment as provided herein)

                          COMMON STOCK PURCHASE WARRANT

No. _________________                               Issue Date:  June 28, 2006

     AMS Health Sciences, Inc., a corporation organized under the laws of the
State of Oklahoma (the "Company"), hereby certifies that, for value received,
ASCENDIANT SECURITIES, LLC, or assigns (the "Holder"), is entitled, subject to
the terms set forth below, to purchase from the Company (as defined herein) from
and after the Issue Date of this Warrant and at any time or from time to time
before 5:00 p.m., New York time, through the close of business June 28, 2013
(the "Expiration Date"), up to 495,543 fully paid and nonassessable shares of
Common Stock (as hereinafter defined), $0.0001 par value per share, at the
applicable Exercise Price per share (as defined below). The number and character
of such shares of Common Stock and the applicable Exercise Price per share are
subject to adjustment as provided herein.

     As used herein the following terms, unless the context otherwise requires,
have the following respective meanings:

          (a) The term "Company" shall include AMS Health Sciences, Inc. and any
     person or entity which shall succeed, or assume the obligations of, AMS
     Health Sciences, Inc. hereunder.

          (b) The term "Common Stock" includes (i) the Company's Common Stock,
     par value $0.0001 per share; and (ii) any other securities into which or
     for which any of the securities described in the preceding clause (i) may
     be converted or exchanged pursuant to a plan of recapitalization,
     reorganization, merger, sale of assets or otherwise.

          (c) The term "Other Securities" refers to any stock (other than Common
     Stock) and other securities of the Company or any other person (corporate
     or otherwise) which the holder of the Warrant at any time shall be entitled
     to receive, or shall have received, on the exercise of the Warrant, in lieu
     of or in addition to Common Stock, or which at any time shall be issuable
     or shall have been issued in exchange for or in replacement of Common Stock
     or Other Securities pursuant to Section 4 or otherwise.

          (d) The "Exercise Price" applicable under this Warrant is $.51.

1.   Exercise of Warrant.

     1.1. Number of Shares Issuable upon Exercise. From and after the date
hereof through and including the Expiration Date, the Holder shall be entitled
to receive, upon exercise of this Warrant in whole or in part, by delivery of an
original or fax copy of an exercise notice in the form attached hereto as
Exhibit A (the "Exercise Notice"), shares of Common Stock of the Company,
subject to adjustment pursuant to Section 4.

     1.2. Fair Market Value. For purposes hereof, the "Fair Market Value" of a
share of Common Stock as of a particular date (the "Determination Date") shall
mean:

          (a) If the Company's Common Stock is traded on the American Stock
     Exchange or another national exchange or is quoted on the National or
     Capital Market of The Nasdaq Stock Market, Inc. ("Nasdaq"), then the
     closing or last sale price, respectively, reported for the last business
     day immediately preceding the Determination Date.

          (b) If the Company's Common Stock is not traded on the American Stock
     Exchange or another national exchange or on the Nasdaq but is traded on the
     NASD Over the Counter Bulletin Board, then the mean of the average of the
     closing bid and asked prices reported for the last business day immediately
     preceding the Determination Date.

          (c) Except as provided in clause (d) below, if the Company's Common
     Stock is not publicly traded, then as the Holder and the Company agree or
     in the absence of agreement by arbitration in accordance with the rules
     then in effect of the American Arbitration Association, before a single
     arbitrator to be chosen from a panel of persons qualified by education and
     training to pass on the matter to be decided.

          (d) If the Determination Date is the date of a liquidation,
     dissolution or winding up, or any event deemed to be a liquidation,
     dissolution or winding up pursuant to the Company's charter, then all
     amounts to be payable per share to holders of the Common Stock pursuant to
     the charter in the event of such liquidation, dissolution or winding up,
     plus all other amounts to be payable per share in respect of the Common
     Stock in liquidation under the charter, assuming for the purposes of this
     clause (d) that all of the shares of Common Stock then issuable upon
     exercise of the Warrant are outstanding at the Determination Date.

     1.3. Company Acknowledgment. The Company will, at the time of the exercise
of this Warrant, upon the request of the holder hereof acknowledge in writing
its continuing obligation to afford to such holder any rights to which such
holder shall continue to be entitled after such exercise in accordance with the
provisions of this Warrant. If the holder shall fail to make any such request,
such failure shall not affect the continuing obligation of the Company to afford
to such holder any such rights.

     1.4. Trustee for Warrant Holders. In the event that a bank or trust company
shall have been appointed as trustee for the holders of this Warrant pursuant to
Subsection 3.2, such bank or trust company shall have all the powers and duties
of a warrant agent (as hereinafter described) and shall accept, in its own name
for the account of the Company or such successor person as may be entitled
thereto, all amounts otherwise payable to the Company or such successor, as the
case may be, on exercise of this Warrant pursuant to this Section 1.

2.   Procedure for Exercise.

     2.1. Delivery of Stock Certificates, Etc., on Exercise. The Company agrees
that the shares of Common Stock purchased upon exercise of this Warrant shall be
deemed to be issued to the Holder as the record owner of such shares as of the
close of business on the date on which this Warrant shall have been surrendered
and payment made for such shares in accordance herewith. As soon as practicable
after the exercise of this Warrant in full or in part, and in any event within
three (3) business days thereafter, the Company at its expense (including the
payment by it of any applicable issue taxes) will cause to be issued in the name
of and delivered to the Holder, or as such Holder (upon payment by such Holder
of any applicable transfer taxes) may direct in compliance with applicable
securities laws, a certificate or certificates for the number of duly and
validly issued, fully paid and nonassessable shares of Common Stock (or Other
Securities) to which such Holder shall be entitled on such exercise, plus, in
lieu of any fractional share to which such holder would otherwise be entitled,
cash equal to such fraction multiplied by the then Fair Market Value of one full
share, together with any other stock or other securities and property (including
cash, where applicable) to which such Holder is entitled upon such exercise
pursuant to Section 1 or otherwise.

     2.2. Exercise.

          (a) Payment may be made either (i) in cash or by certified or official
     bank check payable to the order of the Company equal to the applicable
     aggregate Exercise Price, (ii) by delivery of this Warrant, or shares of
     Common Stock and/or Common Stock receivable upon exercise of this Warrant
     in accordance with the formula set forth in subsection (b) below, or (iii)
     by a combination of any of the foregoing methods, for the number of Common
     Shares specified in such Exercise Notice (as such exercise number shall be
     adjusted to reflect any adjustment in the total number of shares of Common
     Stock issuable to the Holder per the terms of this Warrant) and the Holder
     shall thereupon be entitled to receive the number of duly authorized,
     validly issued, fully-paid and non-assessable shares of Common Stock (or
     Other Securities) determined as provided herein.

          (b) Notwithstanding any provisions herein to the contrary, if the Fair
     Market Value of one share of Common Stock is greater than the Exercise
     Price (at the date of calculation as set forth below), in lieu of
     exercising this Warrant for cash, the Holder may elect to receive shares
     equal to the value (as determined below) of this Warrant (or the portion
     thereof being exercised) by surrender of this Warrant at the principal
     office of the Company together with the properly endorsed Exercise Notice
     in which event the Company shall issue to the Holder a number of shares of
     Common Stock computed using the following formula:

        X=                  Y(A-B)
                            ------
                              A

        Where X =  the number of shares of Common Stock to be issued
                   to the Holder

        Y =        the  number of shares of Common  Stock  purchasable  under
                   this  Warrant  or, if only a portion of this Warrant is
                   being exercised,  the portion of this Warrant being exercised
                   (at the date of such calculation)

        A =        the Fair Market  Value of one share of the  Company's
                   Common Stock (at the date of such calculation)

        B =        the Exercise Price per share (as adjusted to the date of
                   such calculation)

3.   Effect of Reorganization, Etc.; Adjustment of Exercise Price.

     3.1. Reorganization, Consolidation, Merger, Etc. In case at any time or
from time to time, the Company shall (a) effect a reorganization, (b)
consolidate with or merge into any other person, or (c) transfer all or
substantially all of its properties or assets to any other person under any plan
or arrangement contemplating the dissolution of the Company, then, in each such
case, as a condition to the consummation of such a transaction, proper and
adequate provision shall be made by the Company whereby the Holder, on the
exercise hereof as provided in Section 1 at any time after the consummation of
such reorganization, consolidation or merger or the effective date of such
dissolution, as the case may be, shall receive, in lieu of the Common Stock (or
Other Securities) issuable on such exercise prior to such consummation or such
effective date, the stock and other securities and property (including cash) to
which such Holder would have been entitled upon such consummation or in
connection with such dissolution, as the case may be, if such Holder had so
exercised this Warrant, immediately prior thereto, all subject to further
adjustment thereafter as provided in Section 4.

     3.2. Dissolution. In the event of any dissolution of the Company following
the transfer of all or substantially all of its properties or assets, the
Company, concurrently with any distributions made to holders of its Common
Stock, shall at its expense deliver or cause to be delivered to the Holder the
stock and other securities and property (including cash, where applicable)
receivable by the Holder pursuant to Section 3.1, or, if the Holder shall so
instruct the Company, to a bank or trust company specified by the Holder and
having its principal office in New York, NY as trustee for the Holder (the
"Trustee").

     3.3. Continuation of Terms. Upon any reorganization, consolidation, merger
or transfer (and any dissolution following any transfer) referred to in this
Section 3, this Warrant shall continue in full force and effect and the terms
hereof shall be applicable to the shares of stock and other securities and
property receivable on the exercise of this Warrant after the consummation of
such reorganization, consolidation or merger or the effective date of
dissolution following any such transfer, as the case may be, and shall be
binding upon the issuer of any such stock or other securities, including, in the
case of any such transfer, the person acquiring all or substantially all of the
properties or assets of the Company, whether or not such person shall have
expressly assumed the terms of this Warrant as provided in Section 4. In the
event this Warrant does not continue in full force and effect after the
consummation of the transactions described in this Section 3, then the Company's
securities and property (including cash, where applicable) receivable by the
Holder will be delivered to the Holder or the Trustee as contemplated by Section
3.2.

4.    Extraordinary Events Regarding Common Stock. In the event that the
Company shall (a) issue additional shares of the Common Stock as a dividend or
other distribution on outstanding Common Stock or any preferred stock issued by
the Company (b) subdivide its outstanding shares of Common Stock, or (c) combine
its outstanding shares of the Common Stock into a smaller number of shares of
the Common Stock, then, in each such event, the Exercise Price shall,
simultaneously with the happening of such event, be adjusted by multiplying the
then Exercise Price by a fraction, the numerator of which shall be the number of
shares of Common Stock outstanding immediately prior to such event and the
denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event, and the product so obtained shall thereafter be
the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be
readjusted in the same manner upon the happening of any successive event or
events described herein in this Section 4. The number of shares of Common Stock
that the Holder shall thereafter, on the exercise hereof as provided in Section
1, be entitled to receive shall be adjusted to a number determined by
multiplying the number of shares of Common Stock that would otherwise (but for
the provisions of this Section 4) be issuable on such exercise by a fraction of
which (a) the numerator is the Exercise Price that would otherwise (but for the
provisions of this Section 4) be in effect, and (b) the denominator is the
Exercise Price in effect on the date of such exercise (taking into account the
provisions of this Section 4). Notwithstanding the foregoing, in no event shall
the Exercise Price be less than the par value of the Common Stock.

5.    Certificate as to Adjustments. In each case of any adjustment or
readjustment in the shares of Common Stock (or Other Securities) issuable on the
exercise of this Warrant, the Company at its expense will promptly cause its
Chief Financial Officer or other appropriate designee to compute such adjustment
or readjustment in accordance with the terms of this Warrant and prepare a
certificate setting forth such adjustment or readjustment and showing in detail
the facts upon which such adjustment or readjustment is based, including a
statement of (a) the consideration received or receivable by the Company for any
additional shares of Common Stock (or Other Securities) issued or sold or deemed
to have been issued or sold, (b) the number of shares of Common Stock (or Other
Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price
and the number of shares of Common Stock to be received upon exercise of this
Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith
mail a copy of each such certificate to the Holder and any Warrant agent of the
Company (appointed pursuant to Section 11 hereof).

6.    Reservation of Stock, Etc., Issuable on Exercise of Warrant. The Company
will at all times reserve and keep available, solely for issuance and delivery
on the exercise of this Warrant, shares of Common Stock (or Other Securities)
from time to time issuable on the exercise of this Warrant.

7.    Assignment; Exchange of Warrant. Subject to compliance with applicable
securities laws, this Warrant, and the rights evidenced hereby, may be
transferred by any registered holder hereof (a "Transferor") in whole or in
part. On the surrender for exchange of this Warrant, with the Transferor's
endorsement in the form of Exhibit B attached hereto (the "Transferor
Endorsement Form") and together with evidence reasonably satisfactory to the
Company demonstrating compliance with applicable securities laws, which shall
include, without limitation, the provision of a legal opinion from the
Transferor's counsel (at the Company's expense) that such transfer is exempt
from the registration requirements of applicable securities laws, the Company at
its expense (but with payment by the Transferor of any applicable transfer
taxes) will issue and deliver to or on the order of the Transferor thereof a new
Warrant of like tenor, in the name of the Transferor and/or the transferee(s)
specified in such Transferor Endorsement Form (each a "Transferee"), calling in
the aggregate on the face or faces thereof for the number of shares of Common
Stock called for on the face or faces of the Warrant so surrendered by the
Transferor.

8.    Replacement of Warrant. On receipt of evidence reasonably satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant
and, in the case of any such loss, theft or destruction of this Warrant, on
delivery of an indemnity agreement or security reasonably satisfactory in form
and amount to the Company or, in the case of any such mutilation, on surrender
and cancellation of this Warrant, the Company at its expense will execute and
deliver, in lieu thereof, a new Warrant of like tenor.

9.    Registration Rights. The Holder has been granted certain piggyback
registration rights by the Company.

10.   Maximum Exercise. Notwithstanding anything herein to the contrary, in
no event shall the Holder be entitled to exercise any portion of this Warrant in
excess of that portion of this Warrant upon exercise of which the sum of (1) the
number of shares of Common Stock beneficially owned by the Holder and its
Affiliates (other than shares of Common Stock which may be deemed beneficially
owned through the ownership of the unexercised portion of the Warrant or the
unexercised or unconverted portion of any other security of the Holder subject
to a limitation on conversion analogous to the limitations contained herein) and
(2) the number of shares of Common Stock issuable upon the exercise of the
portion of this Warrant with respect to which the determination of this proviso
is being made, would result in beneficial ownership by the Holder and its
Affiliates of any amount greater than 4.99% of the then outstanding shares of
Common Stock (whether or not, at the time of such exercise, the Holder and its
Affiliates beneficially own more than 4.99% of the then outstanding shares of
Common Stock). As used herein, the term "Affiliate" means any person or entity
that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a person or entity, as such terms
are used in and construed under Rule 144 under the Securities Act. For purposes
of the proviso to the second preceding sentence, beneficial ownership shall be
determined in accordance with Section 13(d) of the Securities Exchange Act of
1934, as amended, and Regulations 13D-G thereunder, except as otherwise provided
in clause (1) of such proviso. The limitations set forth herein may be waived by
the Holder upon provision of no less than sixty-one (61) days prior notice to
the Company.

11.   Warrant Agent. The Company may, by written notice to the each Holder of
the Warrant, appoint an agent for the purpose of issuing Common Stock (or Other
Securities) on the exercise of this Warrant pursuant to Section 1, exchanging
this Warrant pursuant to Section 7, and replacing this Warrant pursuant to
Section 8, or any of the foregoing, and thereafter any such issuance, exchange
or replacement, as the case may be, shall be made at such office by such agent.

12.   Transfer on the Company's Books. Until this Warrant is transferred on
the books of the Company, the Company may treat the registered holder hereof as
the absolute owner hereof for all purposes, notwithstanding any notice to the
contrary.

13.   Notices, Etc. All notices and other communications from the Company to
the Holder shall be mailed by first class registered or certified mail, postage
prepaid, at such address as may have been furnished to the Company in writing by
such Holder or, until any such Holder furnishes to the Company an address, then
to, and at the address of, the last Holder who has so furnished an address to
the Company.

14.   Miscellaneous. This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is
sought. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS.
ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT
SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS
LOCATED IN THE STATE OF NEW YORK; PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE
TO WAIVE THIS PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The
individuals executing this Warrant on behalf of the Company agree to submit to
the jurisdiction of such courts and waive trial by jury. The prevailing party
shall be entitled to recover from the other party its reasonable attorneys' fees
and costs. In the event that any provision of this Warrant is invalid or
unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and
shall be deemed modified to conform with such statute or rule of law. Any such
provision which may prove invalid or unenforceable under any law shall not
affect the validity or enforceability of any other provision of this Warrant.
The headings in this Warrant are for purposes of reference only, and shall not
limit or otherwise affect any of the terms hereof. The invalidity or
unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision hereof. The Company acknowledges that
legal counsel participated in the preparation of this Warrant and, therefore,
stipulates that the rule of construction that ambiguities are to be resolved
against the drafting party shall not be applied in the interpretation of this
Warrant to favor any party against the other party.

                   [BALANCE OF PAGE INTENTIONALLY LEFT BLANK;
                             SIGNATURE PAGE FOLLOWS]

     IN WITNESS WHEREOF, the Company has executed this Warrant as of the date
first written above.

                                      AMS HEALTH SCIENCES, INC.

WITNESS:
                                      By:  /s/ Jerry W. Grizzle
                                      Name:    Jerry W. Grizzle
                                      Title: Chairman, President and CEO

<PAGE>
                                    Exhibit A

                              FORM OF SUBSCRIPTION
                   (To Be Signed Only On Exercise Of Warrant)

TO:  AMS Health Sciences, Inc.

Attention: Chief Financial Officer

     The undersigned, pursuant to the provisions set forth in the attached
Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

________    ________ shares of the Common Stock covered by such Warrant; or

________    the maximum  number of shares of Common Stock  covered by such
            Warrant pursuant to the cashless exercise procedure set forth
            in Section 2.

     The undersigned herewith makes payment of the full Exercise Price for such
shares at the price per share provided for in such Warrant, which is
$___________. Such payment takes the form of (check applicable box or boxes):

________    $__________ in lawful money of the United States; and/or

________    the  cancellation  of such  portion  of the  attached  Warrant as
            is  exercisable  for a total of _______  shares of Common  Stock
            (using a Fair Market Value of $_______ per share for purposes of
            this calculation); and/or

________    the  cancellation  of such number of shares of Common Stock as
            is necessary,  in accordance  with the  formula  set forth in
            Section  2.2, to exercise  this  Warrant  with  respect to the
            maximum number of shares of Common Stock  purchasable  pursuant
            to the cashless  exercise  procedure set forth in Section 2.

     The undersigned requests that the certificates for such shares be issued in
the name of, and delivered to ______________________________________________
whose address is
___________________________________________________________________________.

     The undersigned represents and warrants that all offers and sales by the
undersigned of the securities issuable upon exercise of the within Warrant shall
be made pursuant to registration of the Common Stock under the Securities Act of
1933, as amended (the "Securities Act") or pursuant to an exemption from
registration under the Securities Act.

Dated:
                               (Signature must conform to name of holder as
                               specified on the face of the Warrant)

                               Address:

<PAGE>
                                    Exhibit B

                         FORM OF TRANSFEROR ENDORSEMENT
                   (To Be Signed Only On Transfer Of Warrant)

     For value received, the undersigned hereby sells, assigns, and transfers
unto the person(s) named below under the heading "Transferees" the right
represented by the within Warrant to purchase the percentage and number of
shares of Common Stock of AMS Health Sciences, Inc. into which the within
Warrant relates specified under the headings "Percentage Transferred" and
"Number Transferred," respectively, opposite the name(s) of such person(s) and
appoints each such person Attorney to transfer its respective right on the books
of AMS Health Sciences, Inc. with full power of substitution in the premises.

                                             Percentage              Number
Transferees             Address              Transferred           Transferred

Dated:
                              (Signature must conform to name of holder as
                              specified on the face of the Warrant)

                              Address:

                              SIGNED IN THE PRESENCE OF:

                              (Name)
ACCEPTED AND AGREED:
[TRANSFEREE]

             (Name)EXHIBIT 10.22

                           ASCENDIANT SECURITIES, LLC
          18881 Von Karman Avenue, Suite 1630, Irvine, California 92612
         Tel: (949) 756-1010 | Fax: (949) 756-1090 | www.ascendiant.com
                                Member NASD/SIPC

                                                              [Logo]

March 15, 2006

Mr. Jerry W. Grizzle                                 (Sent via Electronic Mail)
Chairman, President and Chief Executive Officer
AMS Health Sciences, Inc.
711 NE 39th Street
Oklahoma City, OK 73105

Dear Jerry,

Thank you for the opportunity to work with you and your company, AMS Health
Services, Inc.

This letter agreement (the "Agreement") confirms that AMS Health Services, Inc.
("Client") has engaged Ascendiant Securities, LLC ("Ascendiant") to act on a
best efforts basis as financial advisor and non-exclusive placement agent for
the Client in connection with the structuring, issuance, and sale (the
"Transaction(s)") of debt and/or equity securities (the "Securities") for
financing purposes. Ascendiant Securities, LLC is an investment banking firm
registered as a broker-dealer with the U.S. Securities and Exchange Commission
(SEC), and member of the NASD and SIPC.

Accordingly, we mutually agree as follows:

1.   Transactions. Ascendiant anticipates one or more Transactions, involving
     the sale of the Client's Securities to institutional and/or accredited
     investors ("Investor" or "Investors"). The actual terms and structure of
     each Transaction will depend on market conditions and will be subject to
     negotiation between the Client and Ascendiant and prospective Investors.

2.   Engagement. In connection herewith, Ascendiant shall provide the following
     financial advisory and placement agent services on a best efforts basis to
     the Client:

     a.   advise the Client with respect to the form and structure of each
          Transaction;

     b.   assist the Client in developing any necessary materials;

     c.   identify and make contact with prospective Investors;

     d.   assist the Client in conducting presentations and due diligence
          meetings with prospective Investors; and

     e.   provide such other financial advisory and investment banking services
          as are reasonably necessary to consummate each Transaction.

Ascendiant shall devote such time and efforts to the affairs of the Client as is
reasonably necessary to render the services contemplated by this Agreement. Any
work or task of Ascendiant provided for herein which requires Client to provide
certain information to assist Ascendiant in completion of the work shall be
excused (without effect upon any obligation of Client) until such time as Client
has fully provided all information and cooperation necessary for Ascendiant to
complete the work. The services of Ascendiant shall not include the rendering of
any legal opinions or the performance of any work that is in the ordinary
purview of a certified public accountant.

It is expressly understood and agreed that Ascendiant shall have no power to
bind Client to any Transaction or contract obligation. Client shall have the
right to refuse any Transaction proposal presented to it without incurring any
obligations to Ascendiant. However, if and when an Ascendiant term sheet is
signed by the Client, this Agreement shall become exclusive and in effect, and
any and all financing from any investors is accepted by Client during the ninety
(90) period following the signing of the term sheet, whether or not that occurs
during the term of this Agreement, shall trigger the Success Fee and Warrants as
described in Sections 3 and 4.

It is understood and agreed that the execution of this Agreement shall not be
deemed or construed as obligating Ascendiant to purchase any of the Securities
and there is no obligation on the part of Ascendiant to place the Securities.
Although Ascendiant cannot guarantee results on behalf of the Client, it shall
use its best efforts to provide the services listed above.

3.   Success Fee. Client agrees that should Client accept and complete any
     Transaction(s), which includes without limitation proceeds from any common
     stock offerings, convertible debt or equity securities, additional
     investment rights, block trade transactions, or exercise of associated
     warrants or options ("Securities") from any Investors introduced by
     Ascendiant during the term of this Agreement, which is defined in Section 6
     below, or if Client should for a period of thirty-six (36) months following
     the termination of this Agreement (including extensions) accept financing
     from any Investors introduced, or contacted on Client's behalf, by
     Ascendiant, there shall become due and payable via wire transfer to
     Ascendiant immediately upon consummation of each Transaction, a cash fee
     equal to eight percent (8%) of the gross proceeds from the sale of
     Securities. Should Ascendiant not be paid within five (5) business days
     after the completion of a Transaction, a service charge shall accrue from
     the date of the Transaction at the rate of 1.5% per month.

4.   Warrants. Client agrees that should Client accept and complete any
     Transaction(s) which includes proceeds from any common stock offerings
     and/or convertible debt or equity securities, or completion of a Securities
     transaction as provided in Section 3 above, from any Investors introduced
     by Ascendiant during the term of this Agreement, which is defined in
     Section 6 below, or if Client should for a period of thirty-six (36) months
     following the termination of this Agreement (including extensions) accept
     financing from any Investors introduced, or previously contacted on
     Client's behalf, by Ascendiant, there shall become due and payable to
     Ascendiant warrants for the purchase of an amount equal to eight percent
     (8%) of the Securities issuable in connection with the Transaction. The
     warrants shall be exercisable into common stock, and will have a term
     consistent with the warrants issued to the Investors with an exercise price
     equal to the closing bid price on the date of the Transaction. The warrants
     shall contain piggyback registration rights and a net exercise provision.

5.   Expenses. If the Client requests that Ascendiant travel outside of Southern
     California to perform the services described herein, whether or not a
     Transaction is consummated, Client shall reimburse Ascendiant for
     travel-related expenses and payment shall be made within seven (7) days of
     invoice. The Client agrees that it will engage its legal counsel at its own
     expense to assist in the preparation of any legal documents or definitive
     agreements deemed necessary to facilitate the Transaction(s) contemplated
     herein.

6.   Term. The term of this Agreement shall be six (6) months from the date of
     Client's execution of this Agreement. Additional extensions may be
     negotiated as necessary at the mutual written consent of the Client and
     Ascendiant. Should Ascendiant successfully complete a Transaction
     generating gross proceeds to Client of $1,500,000 or more, Client agrees to
     extend this Agreement for twelve (12) months from the date of the
     Transaction, with Ascendiant serving as Client's exclusive placement agent
     with respect to institutional equity funds managed by groups domiciled in
     the United States. Upon the completion of the Transaction referenced herein
     generating gross proceeds to Client of $1,500,000 or more, Client shall,
     within three business days of the Transaction, issue to Ascendiant 250,000
     shares of Client's restricted common stock Said shares shall be included in
     the registration statement to be filed in connection with the Transaction
     referenced herein.

7.   Representations, Warranties, and Indemnification. Each of Ascendiant and
     Client represents and warrants to each other that this Agreement has been
     duly authorized, executed and delivered by it; and, assuming the due
     execution by the other party, constitutes a legal, valid and binding
     agreement of it, enforceable against it in accordance with its terms. Each
     of Ascendiant and Client agrees to comply with all applicable securities
     laws, and the Client will disclose to Ascendiant all information necessary
     for Ascendiant to act upon Client's request and to notify Ascendiant
     promptly of any material changes to such information. Client hereby
     represents that it shall notify Ascendiant within three (3) business days
     of the completion of any Securities Transaction(s) occurring during the
     term of this Agreement and/or involving Investors introduced by Ascendiant.
     Additionally, each of the Client and Ascendiant agrees to indemnify the
     other and the other's affiliates in accordance with the terms and
     conditions contained in Exhibit A to this Agreement.

8.   Confidentiality. Ascendiant and Client each agree to keep confidential and
     provide reasonable security measures to keep confidential information where
     release may be detrimental to their respective business interests.
     Ascendiant and Client shall each require their employees, agents,
     affiliates, other licensees, and others who will have access to the
     information through Ascendiant and Client respectively, to abide by the
     confidentiality provisions contemplated by this Agreement in perpetuity.
     Ascendiant will not, either during its engagement by the Client pursuant to
     this Agreement or at any time thereafter, disclose, use or make known for
     its or another's benefit any confidential information, knowledge, or data
     of the Client or any of its affiliates in any way acquired or used by
     Ascendiant during its engagement by the Client. Confidential information,
     knowledge or data of the Client and its affiliates shall not include any
     information that is, or becomes generally available to the public other
     than as a result of a disclosure by Ascendiant or its representatives.
     Notwithstanding the foregoing, Client hereby authorizes Ascendiant to
     transmit to prospective Investors, information and materials provided by
     Client and/or developed by Ascendiant on behalf of Client upon approval by
     Client of such materials. Additionally, at any time after the consummation
     or other public announcement of the Transaction, Ascendiant may, at its own
     expense, place an announcement in such newspapers and publications as it
     may choose, stating that Ascendiant has acted as financial advisor and
     placement agent to the Client in connection with the Transaction, and may
     use, from time to time, the Client's name and logo and a brief description
     of the Transaction in publications and/or marketing materials prepared
     and/or distributed by Ascendiant.

9.   Non-Circumvention. In and for valuable consideration, Client hereby agrees
     that Ascendiant may introduce (whether by written, oral, data, or other
     form of communication) Client to one or more Investors, including, without
     limitation, natural persons, corporations, limited liability companies,
     partnerships, unincorporated businesses, sole proprietorships and similar
     entities (hereinafter an "Investor" or "Investors"). Client further
     acknowledges and agrees that the identity of the subject Investors, and all
     other information concerning Investors (including without limitation, all
     mailing information, phone and fax numbers, email addresses and other
     contact information) introduced hereunder are the property of Ascendiant,
     and shall be treated as confidential and proprietary information by Client,
     its affiliates, officers, directors, shareholders, employees, agents,
     representatives, successors and assigns. Client shall not use such
     information, except in the context of any arrangement with Ascendiant in
     which Ascendiant is directly and actively involved, and never without
     Ascendiant's prior written approval. Client further agrees that neither it
     nor its employees, affiliates or assigns, shall enter into, or otherwise
     arrange (either for it/him/herself, or any other person or entity), any
     Transaction, business relationship, meeting, phone call, or other
     correspondence with such Investors, either directly or indirectly, or
     accept any Transaction, compensation or advantage in relation to such
     Investors, except as directly though Ascendiant, without the prior written
     approval of Ascendiant. Ascendiant is relying on Client's assent to these
     terms and their intent to be bound by the terms by evidence of their
     signature. Without Client's signed assent to these terms, Ascendiant would
     not introduce any Investors or disclose any confidential information to
     Client as herein described.

10.  Governing Law. This Agreement shall be governed by and construed in
     accordance with the laws of the State of California applicable to contracts
     executed and to be wholly performed therein without regard to its conflict
     of law doctrine. The Client and Ascendiant hereby agree that any dispute
     concerning this Agreement shall be resolved through binding arbitration
     before the NASD in Los Angeles County pursuant to its arbitration rules.
     The prevailing party shall be entitled, in addition to such other relief
     that may be granted, to a reasonable sum of attorney's fees and any other
     costs and expenses relating thereto.

11.  Entire Agreement. This Agreement represents the entire agreement by and
     between the Client and Ascendiant and supersedes any and all other
     agreements, either oral or written, with respect to the Agreement. Each
     party to this Agreement acknowledges that no representation, inducements,
     promises or agreement, orally or otherwise, have been made by any party, or
     anyone acting on behalf of any party, which are not embodied herein, and
     that no other agreement, statement, or promise not contained in this
     Agreement shall be valid or binding. The Client and Ascendiant hereby agree
     that the opening and closing statements of this Agreement are incorporated
     herein by this reference and made a material part of this Agreement. If any
     part of this Agreement is found, or deemed by a court of competent
     jurisdiction, to be invalid or unenforceable, that part shall be severable
     from the remainder of the Agreement. This Agreement may be executed
     simultaneously in two or more counterparts, each of which shall be deemed
     an original, but all of which shall constitute one and the same instrument.
     Any modification of this Agreement will be effective only if it is in
     writing and signed by the Client and Ascendiant.

12.  Survival of Certain Provisions. Sections 3, 4, 5, 6, 7, 8, 9, 10, 12 and
     Exhibit A of this Agreement shall survive this Agreement, and remain
     operative and in full force and effect, regardless of, (i) the completion
     of any Transaction, (ii) the resignation of Ascendiant or any termination
     of Ascendiant's services, or (iii) any amendment, expiration or termination
     of this Agreement, and shall be binding upon, and shall inure to the
     benefit or, any successors, assigns, heirs and personal representatives of
     the Client, Ascendiant, and the Indemnified Persons.

Please initial each page, sign below, and return an original and one copy of
this letter to the undersigned to indicate your acceptance of the terms set
forth herein, whereupon this letter and your acceptance shall constitute a
binding agreement by and between AMS Health Sciences, Inc. and Ascendiant
Securities, LLC as of the date first above written. We appreciate the
opportunity to be of service and look forward to a cooperative working
relationship with you and your staff.

Sincerely,                                   Accepted and Agreed:

Ascendiant Securities, LLC                   AMS Health Sciences, Inc.

  /s/ Bradley J. Wilhite                       /s/ Jerry W. Grizzle
By: Bradley J. Wilhite                       By: Jerry W. Grizzle
Its: Managing Director                       Its: Chairman, President and CEO
Date: March 15, 2006                         Date: March 22, 2006

<PAGE>

                                    EXHIBIT A

This Exhibit A is a part of and is incorporated into that certain letter
agreement between AMS Health Sciences, Inc. (the "Client") and Ascendiant
Securities, LLC ("Ascendiant"). The letter agreement and this Exhibit A are
referred to herein as the "Agreement". Capitalized terms used herein without
definition shall have the meanings ascribed to them in the letter agreement.

Each of the Client and Ascendiant (each an "Indemnifying Party") agrees to
indemnify and hold harmless the other, any affiliates and the respective
officers, directors, partners, employees, representatives and agents and any
other persons controlling the other or any affiliates within the meaning of the
Securities Act of 1933 or the Securities Exchange Act of 1934 (each such person
or entity being referred to as an "Indemnified Person"), to the fullest extent
lawful, from and against, and the Indemnified Persons shall have no liability to
the Indemnifying Party or its owners, affiliates, controlling persons, security
holders or creditors for, all claims, liabilities, losses, damages and expenses,
including without limitation and as incurred, reimbursement of all costs of
investigating, preparing, pursuing, or defending any such claim or action,
including fees and expenses of counsel to, and the per diem costs and expenses
of personnel of, the Indemnified Person (collectively, "Losses"), whether or not
arising out of pending or threatened litigation, governmental investigation,
arbitration or other alternative dispute resolution, or other action or
proceeding (individually a "Proceeding" and collectively "Proceedings"),
directly or indirectly related to or arising out of, or in connection with (i)
actions taken or omitted to be taken by the Indemnifying Party, its affiliates,
employees, directors, officers, partners, representatives or agents in
connection with any transaction or activities contemplated by this Agreement;
(ii) actions taken or omitted to be taken by any Indemnified Person pursuant to
the terms of, or in connection with services rendered pursuant to, this
Agreement, provided that in the case of this subsection (ii) the Indemnifying
Party shall not be responsible for any Losses arising out of or based upon the
willful misconduct or negligence (as determined by the judgment of a court of
competent jurisdiction, no longer subject to appeal or further review) of or by
such Indemnified Person; and (iii) any untrue statement or alleged untrue
statement of material fact contained in any Information approved by the Client
or any omission or alleged omission to state a material fact necessary to make
the statements therein not misleading (other than untrue statements or alleged
untrue statements in, or omissions or alleged omissions from, information
relating to an Indemnified Person furnished in writing by or on behalf of such
Indemnified Person expressly for use in such Information). If the
indemnification provided for under this Agreement is unavailable to an
Indemnified Person in respect of any Losses, then the Indemnifying Party, in
lieu of indemnifying such Indemnified Person, shall contribute to the amount
paid or payable by such Indemnified Person as a result of such Losses in such
proportion as is appropriate to reflect the relative fault of the Client on the
one hand and the Indemnified Person on the other, as well as any other relevant
equitable considerations. If any Proceeding is commenced as to which an
Indemnified Person demands indemnification, the Indemnified Person shall have
the right to retain counsel of its own choice to represent it, the Indemnifying
Party shall pay the reasonable fees and expenses of such counsel, and such
counsel shall to the extent consistent with its professional responsibilities
cooperate with the Indemnifying Party and any counsel designated by the
Indemnifying Party , provided, that in no event shall the Indemnifying Party be
required to pay fees and expenses under this indemnity for more than one firm of
attorneys for the Indemnified Person in any jurisdiction in any one legal action
or group of related legal actions. The Indemnifying Party shall be liable as
provided herein for any settlement of any claim against Ascendiant or any
Indemnified Person made with the Indemnifying Party's written consent, which
consent shall not be unreasonably withheld. The Indemnifying Party agrees that
it will not, without the prior written consent of Ascendiant, settle or
compromise or consent to the entry of any judgment in any Proceeding (whether or
not any Indemnified Person is a party thereto) unless such settlement,
compromise or consent includes an unconditional release of Ascendiant and each
other Indemnified Person from all liability arising or that may arise out of
such Proceeding. The indemnity and contribution obligations of the Indemnifying
Party set forth herein shall be in addition to any liability or obligation the
Indemnifying Party may have to any Indemnified Person at common law or
otherwise. The Indemnifying Party hereby consents to personal jurisdiction,
service and venue in any court in which any claim, which is subject to this
Agreement, is brought against Ascendiant or any other Indemnified Person.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]